Skip To Main Content
Deepan Chatterjee on Muck Rack

Deepan Chatterjee

Maryland
As seen in: Hello Monday with Jessi Hempel, Medium, HuffPost, Baltimore Sun, BioRxiv, India America Today
1st gen immigrant who loves America. Self-made. Psych Doc. Writer. Speaker. Entrepreneur. Ex-Board Member @APA, @mpapsych Opinionated. Views/opinions my own!
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Deepan

Contact Deepan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Primary care, other routine services, and generic drugs should be direct-to-patient, without insurance. Thank you, Dr. Krishnan Chittur https://lnkd.in/e8knygYn With Brian Uhlig and David Hyman… | Ge Bai | 30 comments

|
By Deepan Chatterjee, Fred Pane, Deborah Williams, Ed Gamache
| LinkedIn
Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy. Skip to main content Explore content categories Create your free account or sign in to continue your search or New to LinkedIn? Join now or New to LinkedIn? Join now By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Open in Who Shared View Duplicates (325) Issue with article?

KSR1 regulates small-cell lung carcinoma tumor initiation and cisplatin resistance

|
By Deepan Chatterjee, Robert A. Svoboda, Dianna H Huisman, Heidi M Vieira
| BioRxiv
Abstract Small-cell lung cancer (SCLC) is designated a recalcitrant cancer due to its five-year relative survival rate of less than 7%. First line SCLC treatment has changed modestly in the last 40 years. The NeuroD1 subtype of SCLC (SCLC-N) commonly harbors MYC amplifications and other hallmarks of aggressive behavior. Finding novel therapeutic options that effectively eliminate residual disease observed after initial response to therapy is essential to improving SCLC patient outcome.
Open in Who Shared Issue with article?

Kinase Suppressor of Ras 2 promotes self-renewal and clonogenicity of small-cell lung carcinoma

|
By Dianna H Huisman, Deepan Chatterjee, Robert A. Svoboda, Heidi M Vieira
| BioRxiv
Abstract Small-cell lung carcinoma (SCLC) tumors are heterogeneous, with a subpopulation of cells primed for tumor initiation. Here, we show that Kinase Suppressor of Ras 2 (KSR2) promotes the self-renewal and clonogenicity of SCLC cells. KSR2 is a molecular scaffold that promotes Raf/MEK/ERK signaling. KSR2 is preferentially expressed in the ASCL1 subtype of SCLC (SCLC-A) tumors and is expressed in pulmonary neuroendocrine cells, one of the identified cells of origin for SCLC-A tumors.
Open in Who Shared Issue with article?
See all 10 licensed articles (22 Total)